The largest-yet clinical study into psilocybin (the hallucinogenic ingredient in magic mushrooms), found that the psychedelic drug is highly effective in reducing symptoms in people with treatment-resistant depression. In the 233-patient study conducted across North America and Europe, Compass Pathways found that patients who received the highest dose, 25mg dose of the compound, saw positive results nearly four times more often than those in the control group who received a placebo-like 1-milligram dose, scoring 6.6 points higher on a rating scale of depression reduction. The results were promising even three weeks after a psilocybin session. The results have not yet been peer-reviewed or published.
Previously On...: Recently, Johns Hopkins Medicine received the first federal grant in the last 50 years from the US National Institutes of Health (NIH) to support research into psychedelic drugs. The $4 million grant, funded by NIH’s National Institute on Drug Abuse, was awarded to explore the impact of psilocybin on tobacco addiction.
